Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop

Executive Summary

The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.


Related Content

Phase III Beckons For A Short-Course Seasonal Allergic Rhinitis Jab
Circassia Builds US Respiratory Presence with AstraZeneca Deal
UK Health-Care Investors ‘Not As Brave Or Audacious’ As Those In US
KO’d By Allergy Failure, Circassia Looks To Respiratory Pipeline For Second Wind
Turmoil In Allergy Market Continues As Merck Ends ALK Partnership
Gloom Is Overblown: Allergy Vaccine Sector Is Poised To Globalize
Stockwatch: Damage Not Controlled
Circassia Uses Adaptive Design For Phase III And Advances Commercial Plans
Circassia paying £188m for two asthma firms, but it's still an allergy specialist
Circassia puts money where mouth is; IPO floats at top price


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts